biotechnology - Publications - Faculty & Research - Harvard Business School

Filter Results: (620)

Filter Results: (620)

Show Results For

← Page 7 of 620 Results →

Gary P. Pisano

Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details

Keywords: biotechnology; biotechnology; biotechnology; biotechnology; biotechnology

June 2005 (Revised July 2006)
Background Note

Note on the Convergence Between Genomics & Information Technology

By: David B. Yoffie, Dharmesh M Mehta and Rachel Sha

Focuses on the convergence between the genomics and semiconductor industries, in particular organ printing, DNA computing, biomolecular sensory networks, and DNA microarrays. Explains what this newly converged world looks like based on current research and findings in... View Details

Keywords: Genetics; Information Technology; Business Model; Disruptive Innovation; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry

Find at Harvard

September 2020 (Revised January 2021)
Case

Catalys Pacific

By: Joshua Lev Krieger

In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After... View Details

Keywords: Pharmaceutical Companies; Biotech; Health Care; Entrepreneur; Innovation; International Business; Entrepreneurial Finance; Entrepreneurship; Finance; Innovation Strategy; Venture Capital; Strategy; Cross-Cultural and Cross-Border Issues; Biotechnology Industry; Biotechnology Industry; Tokyo

Article

Network Effects in the Governance of Strategic Alliances

We argue that the stock of prior alliances between participants in the biotechnology sector forms a network that serves as a governance mechanism in interfirm transactions. To test how this network substitutes for other governance mechanisms, we examine how equity... View Details

Keywords: Network Effects; Governance; Strategy; Alliances; Stocks; Market Transactions; Equity; Mortgages; Biotechnology Industry

Find at Harvard

February 2010
Case

Amyris Biotechnologies: Commercializing Biofuel

By: Gary P. Pisano and Alison Berkley Wagonfeld

In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic biology to convert sugarcane into both renewable fuels and renewable chemicals. The Amyris' marketing team was investigating the commercial interest for both types of products, while the... View Details

Keywords: Renewable Energy; Chemicals; Risk Management; Product Marketing; Product Development; Production; Environmental Sustainability; Commercialization; Biotechnology Industry; Brazil

08 Jan 2018
News

What Do Investors and Companies Talk About?

June 2006 (Revised January 2012)
Case

Teena Lerner: Dividing the Pie at Rx Capital (A)

By: Boris Groysberg, Victoria Winston and Robin Abrahams

Teena Lerner started her own hedge fund firm in 2001 after nearly 20 years as a star biotechnology analyst and hedge fund manager. After the start-up phase, her firm became highly profitable. In 2004, however, one of her four analysts lost a lot of money for the firm.... View Details

Keywords: Managerial Roles; Investment Funds; Performance; Business Startups; Compensation and Benefits; Corporate Finance; Financial Services Industry

10 Jul 2014
News

How Harvard Medical School Uses Open Innovation To Solve World-Class Scientific Problems

May 2007 (Revised September 2008)
Case

Biocon Limited

By: Krishna G. Palepu and Ananth Chepuri

Biocon Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an innovation-led strategy. This new... View Details

Keywords: Globalized Firms and Management; Innovation and Management; Leading Change; Growth and Development Strategy; Risk Management; Organizational Change and Adaptation; Biotechnology Industry; India

June 2018
Teaching Note

Sandra Brown Goes Digital

By: Rosabeth Moss Kanter and Jonathan Cohen

As a middle manager at a biotechnology company, Sandra Brown harnessed digital tools and social media to engage others and build campaigns for change in the company. This Teaching Note presents strategies for teaching the Sandra Brown case series, which follows Brown's... View Details

Keywords: Change Leadership; Change Management; Digital; Engagement; Stakeholder Engagement; Grassroots Movement; Health Care Industry; Career Path; Innovation; Leading Change; Management; Innovation and Management; Personal Development and Career; Organizational Change and Adaptation; Quality

July 2016
Case

Product Portfolio Management at Genentech

By: Kevin Schulman and Jamie Gresh

Genentech, long the darling of the biotechnology industry, was acquired by Swiss pharmaceutical company Roche in 2009. The combined company retains the name Genentech in the US, but must now move to achieve the promises made at the time of this merger—to build from... View Details

Keywords: Portfolio Management; Drug Development; Postmerger Integration; Marketing Strategy; Mergers and Acquisitions; Integration; Biotechnology Industry; Biotechnology Industry; United States

June 2006 (Revised April 2007)
Case

BioScale

By: H. Kent Bowen and Bradley R. Staats

In 2004, Mark Lundstrom must decide on a funding method and strategic approach for BioScale, a biotechnology company that he founded. BioScale has developed a microchip-based bioanalytical platform that can be used to detect very small concentrations of cells, viruses,... View Details

Keywords: Entrepreneurship; Science-Based Business; Capital; Financing and Loans; Partners and Partnerships; Biotechnology Industry

2006
Book

Science Business: The Promise, the Reality, and the Future of Biotech

By: Gary P. Pisano

Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details

Keywords: Science; Business Ventures; Biotechnology Industry

Find at Harvard

November 2018
Case

David Hysong and SHEPHERD Therapeutics

By: Ananth Raman, John Masko and Aldo Sesia

In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his... View Details

Keywords: Cancer; Therapeutics; Drugs; Health Care and Treatment; Business Startups; Product Development; Financing and Loans; Growth and Development Strategy; Problems and Challenges

February 2000 (Revised October 2000)
Case

Kendle International Inc.

By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs

Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and... View Details

Keywords: Acquisition; Financing and Loans; Venture Capital; Stock Options; Banks and Banking; Debt Securities; International Finance; Financial Strategy; Management Skills; Private Ownership; Initial Public Offering; Biotechnology Industry; Biotechnology Industry

December 1999 (Revised August 2001)
Case

Millennium Pharmaceuticals, Inc. (A)

By: Stefan H. Thomke and Ashok Nimgade

Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details

Keywords: Cost Management; Financing and Loans; Medical Specialties; Retention; Growth and Development Strategy; Time Management; Product Development; Problems and Challenges; Alliances; Technology; Biotechnology Industry; Biotechnology Industry; Cambridge

Research Summary

Does the Adoption of Rolling Forecasts Improve Planning?

This field study investigates the consequences of adopting rolling forecasts on organizational planning. Using quarterly product-line forecasted and realized sales data from several business units of a multinational biotechnology supplier, I find that subsequent to the... View Details

April 1993 (Revised October 1995)
Case

ALZA and Bio-Electro Systems (A): Technological and Financial Innovation

By: Josh Lerner and Peter Tufano

To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details

Keywords: Risk and Uncertainty; Technological Innovation; Business Subsidiaries; Decision Choices and Conditions; Corporate Finance; Biotechnology Industry; Biotechnology Industry

Paul A. Gompers

Paul Gompers, Professor of Business Administration at the Harvard Business School, specializes in research on financial issues related to start-up, high growth, and newly public companies. Professor Gompers has an appointment in both the View Details

Keywords: electronics; health care; high technology; information technology industry; investment banking industry; pharmaceuticals; semiconductor; venture capital industry

January 2020
Case

Celata Bioinnovations

By: John R. Wells and Benjamin Weinstock

In December 2019, Jon Hu (HBS ‘19) and Dr. Samantha Dale Strasser, co-founders of Celata Bioinnovations, were raising $1 million to launch their company. They had founded Celata less than six months earlier with the aim of redefining the drug discovery process.... View Details

←
7
8
…
30
31
→